TH2 score with 2 thrombotic risk factors and 2 bleeding risk factors for patients with thrombocytopenia and an indication for antithrombotic therapy
| Risk assessment . | Score . |
|---|---|
| Thrombotic risk factors | |
| High thrombotic risk* | +1 |
| Recent ITP treatment† | +1 |
| Bleeding risk factors | |
| Platelets <20 × 109/L | −1 |
| Major bleed (excluding skin) at presentation‡ | −1 |
| Overall score | Nil or positive (excess thrombotic risk); negative (excess bleeding risk) |
| Risk assessment . | Score . |
|---|---|
| Thrombotic risk factors | |
| High thrombotic risk* | +1 |
| Recent ITP treatment† | +1 |
| Bleeding risk factors | |
| Platelets <20 × 109/L | −1 |
| Major bleed (excluding skin) at presentation‡ | −1 |
| Overall score | Nil or positive (excess thrombotic risk); negative (excess bleeding risk) |
Atrial fibrillation congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke, vascular disease, age 65 to 74 years, and sex category >5; unprovoked, recurrent, or cancer-associated thrombosis; antiphospholipid antibody syndrome.
Intravenous immune globulin within 2 weeks or thrombopoietin receptor agonist or splenectomy within 4 weeks.
Grade 2 by the ITP Bleeding Score.12